-
NeuroNEXT represented at ASENT 2018 Annual Meeting
Network successes and the five-year renewal application were presented at the 2018 Annual Meeting of the American Society for Experimental Neurotherapeutics poster session. The poster, presented March 9 at the meeting’s poster presentation and reception, concluded that NeuroNEXT has met all of its initial goals within the first 7-year funding period; that Network sites hae demonstrated their…
-
Editorial accompanying NN101 primary manuscript compliments NeuroNEXT network
In the same issue where the NN101 SMA primary results were published, the Annals of Neurology also published an accompanying editorial with high praise for the Network. The authors noted that “NeuroNEXT is clearly trying to change the landscape of clinical trials in neurology, helping to empower the academic investigator to pursue research efforts that would otherwise be impossible.”
-
NN104 RHAPSODY Coverage in the San Diego Union-Tribune
Results of the NN104 study were covered in the San Diego Union-Tribune. The article details the development of 3K3A-APC, the study drug, originally developed by The Scripps Research Institute in La Jolla, CA.
-
NN104 RHAPSODY Results Featured in ISC 2018 newsletter and ASA blog post
Final results from the NN104 RHAPSODY trial, which were presented at the International Stroke Conference (ISC) 2018 as a closing event, were subsequently featured in ISC’s Science News as Featured Science and on the American Stroke Association blog “Blogging Stroke.”
-
FDA guidance documents of interest to NeuroNEXT
The FDA released several guidance documents in February, 2018, three of which fall under the NeuroNEXT umbrella: ALS, DMD and Migraine.
-
February 2012 issue of The Lancet Neurology praises formation of NeuroNEXT
Article Summary: In February, 2012, the US National Institute for Neurological Disorders and Stroke (NINDS) is due to announce the first study to be supported by the National Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). With this ambitious new network, NINDS aims to facilitate the progress of new drugs from the laboratory to the clinic, specifically at…
-
Steve Kolb explains NN101-SMA
View Steve Kolb’s video announcement of the NN101 SMA study.
-
NeuroNEXT U01 funding announcement
Please visit the NIH page for information related to the NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) funding mechanism. The FOA is available for applications beginning January 5, 2018, through January 8, 2021.
-
NN102 SPRINT-MS top-line results achieve primary endpoints
MediciNova, the industry sponsor of NN102 SPRINT-MS, announced the positive top-line results from the trial. The second funded NeuroNEXT trial, a study to evaluate the activity, safety, and tolerability of Ibudilast in patients with Multiple Sclerosis (MS), has very promising results for MS treatment. Results indicate that Ibudilast demonstrated a statistically significant reduction in the rate of…
-
President of the Child Neurology Society describes next generation of neurological research
In a January/February 2013 editorial, the president of the Child Neurology Society praises the formation of the NeuroNEXT Network and the possibility for it to rapidly evaluate new treatments for neurological disorders.